AU2006277009A1 - Compositions and methods for treating conditions related to ephrin signaling with cupredoxins - Google Patents

Compositions and methods for treating conditions related to ephrin signaling with cupredoxins Download PDF

Info

Publication number
AU2006277009A1
AU2006277009A1 AU2006277009A AU2006277009A AU2006277009A1 AU 2006277009 A1 AU2006277009 A1 AU 2006277009A1 AU 2006277009 A AU2006277009 A AU 2006277009A AU 2006277009 A AU2006277009 A AU 2006277009A AU 2006277009 A1 AU2006277009 A1 AU 2006277009A1
Authority
AU
Australia
Prior art keywords
cupredoxin
cancer
ephrin
azurin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006277009A
Other languages
English (en)
Inventor
Ananda Chakrabarty
Anita Chaudhari
Tapas Das Gupta
Arsenio Fialho
Tohru Yamada
Yonghua Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois
Original Assignee
University of Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/244,105 external-priority patent/US7691383B2/en
Application filed by University of Illinois filed Critical University of Illinois
Publication of AU2006277009A1 publication Critical patent/AU2006277009A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2006277009A 2005-05-20 2006-05-19 Compositions and methods for treating conditions related to ephrin signaling with cupredoxins Abandoned AU2006277009A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US68281205P 2005-05-20 2005-05-20
US60/682,812 2005-05-20
US11/244,105 2005-10-06
US11/244,105 US7691383B2 (en) 2004-10-07 2005-10-06 Cupredoxin derived transport agents and methods of use thereof
US76474906P 2006-02-03 2006-02-03
US60/764,749 2006-02-03
PCT/US2006/019684 WO2007018671A2 (fr) 2005-05-20 2006-05-19 Compositions et methodes de traitement d'etats associes a la signalisation de l'ephrine au moyen de cupredoxines

Publications (1)

Publication Number Publication Date
AU2006277009A1 true AU2006277009A1 (en) 2007-02-15

Family

ID=37727776

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006277009A Abandoned AU2006277009A1 (en) 2005-05-20 2006-05-19 Compositions and methods for treating conditions related to ephrin signaling with cupredoxins

Country Status (10)

Country Link
EP (1) EP1888106A4 (fr)
JP (1) JP2008539795A (fr)
KR (1) KR20080040631A (fr)
AU (1) AU2006277009A1 (fr)
BR (1) BRPI0612424A2 (fr)
CA (1) CA2608512A1 (fr)
IL (1) IL187138A0 (fr)
MX (1) MX2007014598A (fr)
NO (1) NO20076391L (fr)
WO (1) WO2007018671A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691383B2 (en) 2004-10-07 2010-04-06 The Board Of Trustees Of The University Of Illinois Cupredoxin derived transport agents and methods of use thereof
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US9096663B2 (en) 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
EP1904642A4 (fr) 2005-07-19 2008-11-26 Univ Illinois Agents de transport utiles pour traverser la barriere hemato-encephalique et pour penetrer dans les cellules cancereuses du cerveau, methodes d'utilisation de ces derniers
WO2007024368A2 (fr) * 2005-07-19 2007-03-01 The Board Of Trustees Of The University Of Illinois Compositions et methodes de controle de angiogenese a l'aide de cupredoxines
BRPI0714987A2 (pt) * 2006-09-14 2013-07-30 Trutees Of The University Of Illinoi Board Of composiÇÕes e mÉtodos para a prevenÇço do cÂncer com cupredoxina
EP2117573A4 (fr) * 2007-01-11 2011-02-16 Univ Illinois Compositions et méthodes permettant de traiter des affections associées à la signalisation de l'éphrine avec des cuprexodines et des mutants de celles-ci
MY150621A (en) 2007-08-30 2014-02-14 Daiichi Sankyo Co Ltd Anti-epha2 antibody
KR101102829B1 (ko) * 2008-09-12 2012-01-05 재단법인 제주테크노파크 구멍갈파래 추출물과 그것의 항염증제로서의 용도
CN110090295B (zh) * 2018-01-29 2022-12-23 武汉康理通科技有限公司 Ephrin-B1在制备治疗炎症性肠病的药物中的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030081445A (ko) * 2001-02-15 2003-10-17 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 세포 사멸을 조절하는 세포독성인자
US7491394B2 (en) * 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death

Also Published As

Publication number Publication date
MX2007014598A (es) 2008-02-07
NO20076391L (no) 2008-02-15
EP1888106A4 (fr) 2009-01-14
WO2007018671A2 (fr) 2007-02-15
WO2007018671A3 (fr) 2007-11-22
BRPI0612424A2 (pt) 2009-01-27
KR20080040631A (ko) 2008-05-08
EP1888106A2 (fr) 2008-02-20
JP2008539795A (ja) 2008-11-20
CA2608512A1 (fr) 2007-02-15
IL187138A0 (en) 2008-02-09

Similar Documents

Publication Publication Date Title
US10889621B2 (en) Compositions and methods for treating conditions related to ephrin signaling with Cupredoxins
AU2006277009A1 (en) Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US10058585B2 (en) Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US7511117B2 (en) Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
US7338766B2 (en) Compositions and methods for treating malaria with cupredoxin and cytochrome
US8124055B2 (en) Compositions and methods to control angiogenesis with cupredoxins
KR20080024124A (ko) 쿠프레독신과 시토크롬 ｃ로 ｈｉｖ 감염을 치료하기 위한조성물과 방법
WO2007024368A2 (fr) Compositions et methodes de controle de angiogenese a l'aide de cupredoxines
WO2008086523A2 (fr) Compositions et méthodes permettant de traiter des affections associées à la signalisation de l'éphrine avec des cuprexodines et des mutants de celles-ci
US10266868B2 (en) Compositions for treating HIV infection with cupredoxin and cytochrome C
CN101198351A (zh) 用铜氧还蛋白治疗ephrin信号传导相关性病变的组合物和方法
CN101287502A (zh) 用铜氧还蛋白和细胞色素c治疗hiv感染的组合物和方法

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application